Share this article
Share this article
STOCKHOLM, Feb. 18, 2021 /PRNewswire/ Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the fourth quarter and full-year 2020. Revenue growth for the full-year was 7 per cent with revenue of SEK 15,261 M. Adjusted EBITA was SEK 6,301 M, resulting in an adjusted EBITA margin of 41 per cent for the full year.
October - December
Total revenue of SEK 4,581 M (4,890), -6 per cent (-2 per cent at CER)
Adjusted EBITA
1,2 was SEK 2,177 M (2,380), with an adjusted EBITA margin
1,2 of 48 per cent (49). Adjusted EBITA excludes positive impact from reversal of the CVR liability of SEK 399 M
Kineret® (anakinra) approved in Russia for the treatment of CAPS
News provided by
Share this article
Share this article
STOCKHOLM, Feb. 16, 2021 /PRNewswire/ Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the Ministry of Health of the Russian Federation has approved Kineret (anakinra) for the treatment of Cryopyrin associated periodic syndromes (CAPS). We are excited to announce the approval of this important treatment and we look forward to serving patients with CAPS in Russia, said Norbert Oppitz, Head of Immunology and International at Sobi. Today s announcement also marks a significant milestone for Sobi s future ambition, as Russia is a key market for our geographic expansion strategy over the next five years.
Invitation - Presentation of Sobi's Q4 and FY 2020 results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.